EUVIMEDEUVIMED entdecken
Crossref

Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer

Makoto Nakao, Ryosuke Kinoshita, Mamiko Kuriyama, Hiroko Kiyotoshi, Masahiro Sugihara, Norihisa Takeda, Kazuhiro Ohtakara, Hideki Muramatsu

Anticancer Research · 2024

DOI: 10.21873/anticanres.16877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Makoto Nakao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan; kokoro1979@gmai…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Pretreatment serum cytokeratin 19 fragment (CYFRA21-1) level predicts outcomes in patients with non-small cell lung cancer; however, little is known about the clinical value of serum CYFRA21-1 level in patients with small cell lung cancer (SCLC). The aim of this study was to evaluate the prognostic value of pretreatment serum CYFRA21-1 level in patients with extensive disease (ED)-SCLC treated using platinum-doublet chemotherapy. PATIENTS AND METHODS: We retrospectively analyzed the pretreatment serum CYFRA21-1 levels of patients with ED-SCLC who were treated using first-line platinum-doublet chemotherapy. RESULTS: A total of 98 patients were analyzed. The patients with a high CYFRA21-1 level (≥7.0 ng/ml) (n=29) had significantly shorter progression-free survival (PFS) and overall survival (OS) than the patients with low CYFRA21-1 levels (n=67) [median PFS=118 days vs. 125 days, respectively (p=0.018); median OS=213 days vs. 295 days, respectively (p=0.046)]. In addition, high CYFRA21-1 level was associated with a high refractory relapse rate. CONCLUSION: Serum CYFRA21-1 level may be a prognostic marker for patients with ED-SCLC treated with platinum-doublet chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaHumansKeratin-19PrognosisRetrospective StudiesPlatinumNeoplasm Recurrence, LocalAntigens, NeoplasmBiomarkers, Tumor

Stichwörter der Autor:innen

Small-cell lung cancercytokeratin 19 fragmenttumor marker

Substanzen

antigen CYFRA21.1Keratin-19PlatinumAntigens, NeoplasmBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan; kokoro1979@gmail.com.
  • Department of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan.
  • Department of Radiation Oncology, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Japan.

Zitieren

APA

Nakao, M., Kinoshita, R., Kuriyama, M., Kiyotoshi, H., Sugihara, M., Takeda, N., Ohtakara, K., & Muramatsu, H. (2024). Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16877

Vancouver

Nakao M, Kinoshita R, Kuriyama M, Kiyotoshi H, Sugihara M, Takeda N, et al. Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer. Anticancer Research. 2024. doi:10.21873/anticanres.16877

BibTeX
@article{Nakao2024,
  author = {Nakao, Makoto and Kinoshita, Ryosuke and Kuriyama, Mamiko and Kiyotoshi, Hiroko and Sugihara, Masahiro and Takeda, Norihisa and Ohtakara, Kazuhiro and Muramatsu, Hideki},
  title = {Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16877}
}
Kostenlos starten →